The role of transforming growth factor-beta in Marfan syndrome

Cardiol J. 2013;20(3):227-34. doi: 10.5603/CJ.2013.0066.

Abstract

The starting point, in Marfan syndrome (MFS) appears to be the mutation of fibrillin-1 gene whose deconstructed protein product cannot bind transforming growth factor beta (TGF-b), leading to an increased TGF-b tissue level. The aim of this review is to review the already known features of the cellular signal transduction downstream to TGF-b and its impact on the tissue homeostasis of microfibrils, and elastic fibers. We also investigate current data on the extracellular regulation of TGF-b level including mechanotransduction and the feedback cycles of integrin-dependent and independent activation of the latent TGF-b complex. Together these factors, by the destruction of the connective tissue fibers, may play an important role in the development of the diverse cardiac and extracardiac manifestations of MFS and many of them could be a target of conservative treatment. We present currently investigated drugs for the treatment of the syndrome, and explore possible avenues of research into pathogenesis of MFS in order to improve understanding of the disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Aortic Aneurysm / etiology
  • Aortic Aneurysm / metabolism
  • Aortic Aneurysm / prevention & control
  • Humans
  • Marfan Syndrome / complications
  • Marfan Syndrome / drug therapy
  • Marfan Syndrome / metabolism*
  • Prognosis
  • Signal Transduction* / drug effects
  • Transforming Growth Factor beta / metabolism*

Substances

  • Transforming Growth Factor beta